Comorbidity in an Older Population with Type-2 Diabetes Mellitus: Identification of the Characteristics and Healthcare Utilization of High-Cost Patients by Guerrero-Fernández de Alba, I. et al.
Comorbidity in an Older Population
with Type-2 Diabetes Mellitus:
Identification of the Characteristics
and Healthcare Utilization of
High-Cost Patients
Inmaculada Guerrero-Fernández de Alba1,2, Valentina Orlando3,4*, Valeria M. Monetti 3,4,
Sara Mucherino3,4, Antonio Gimeno-Miguel 1,2*, Olga Vaccaro4,5, Maria João Forjaz6,
Beatriz Poblador Plou1,2, Alexandra Prados-Torres1,2, Gabriele Riccardi5 and
Enrica Menditto3,4
1EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, Miguel Servet University Hospital, Zaragoza,
Spain, 2Health Services Research on Chronic Patients Network (REDISSEC), ISCIII, Madrid, Spain, 3CIRFF, Center of
Pharmacoeconomics and Drug utilization Research, Department of Pharmacy, University of Naples Federico II, Naples, Italy,
4Department of Pharmacy, University of Naples Federico II, Naples, Italy, 5Department of Clinical Medicine and Surgery, University
of Naples Federico II, Naples, Italy, 6National Centre of Epidemiology, Institute of Health Carlos III and REDISSEC, Madrid, Spain
Objectives: Little is known about the specific comorbidities contributing to higher costs in
patientswith type-2 diabetesmellitus (T2DM), particularly in older cases.We aimed to evaluate
the prevalence, type, and cost of comorbidities occurring in older T2DM patients versus older
non-T2DM patients, and the factors associated with high cost (HC) T2DM patients.
Methods: Retrospective cohort study using information from the Campania Region
healthcare database. People aged ≥65 years who received ≥2 prescriptions for
antidiabetic drugs were identified as “T2DM patients.” Comorbidities among T2DM and
non-T2DM groups were assessed through the RxRiskV Index (modified version). T2DM
individuals were classified according to the total cost distribution as HC or “non-high cost.”
Two sub-cohorts of HC T2DM patients were assessed: above 90th and 80th percentile of
the total cost. Age- and sex-adjusted logistic regression models were created.
Results: Among the T2DM cohort, concordant and discordant comorbidities occurred
significantly more frequently than in the non-T2DM cohort. Total mean annual cost per
T2DM patient due to comorbidities was €7,627 versus €4,401 per non-T2DM patient.
Among T2DM patients identified as being above 90th and 80th percentiles of cost
distribution, the total annual costs were >€19,577 and >€2,563, respectively. The
hospitalization cost was higher for T2DM cases. Strongest predictors of being a HC
T2DM patient were having ≥5 comorbidities and renal impairment.
Conclusion: HC patients accrued >80% of the total comorbidities cost in older T2DM
patients. Integrated care models, with holistic and patient-tailored foci, could achieve more
effective T2DM care.
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INTRODUCTION
In the past three decades, the prevalence of type-2 diabetes
mellitus (T2DM) has increased dramatically worldwide to
become an important healthcare concern (World Health
Organization, 2016; Zimmet, 2017). In 2018, T2DM
prevalence in Italy was estimated as 6.2% of the total
population and ∼approximately 67% of T2DM patients are
aged ≥65 years (ARNO diabetes observatory, 2019). The
resulting health and economic impacts go beyond the
condition itself because T2DM patients are subject to
disabling complications, such as cardiovascular or renal
diseases (Van Dieren et al., 2010; Schinner, 2011), and
incur very high costs to the Italian National Health Service
(Hutter et al., 2010; O’Shea et al., 2013; Lehnert et al., 2011).
Piette and Kerr (2006) identified two types of T2DM-
associated comorbidities. They developed a framework in
which chronic conditions are conceptualized as concordant
(pathophysiologic profile or management plan similar to
T2DM) or discordant (pathophysiologic condition and
disease-management plan not directly related to T2DM).
With the increasing burden of T2DM comorbidity, the
aforementioned framework has served as a basis to
improve T2DM management and to study the impact of
multimorbidity (Calderón-Larrañaga et al., 2014; Lin et al.,
2018; Aga et al., 2019). Indeed, a recent study in Spain
demonstrated that the coexistence of mental and other
discordant comorbidities in T2DM patients may increase
the use of healthcare resources significantly (Calderón-
Larrañaga et al., 2015). The economic impact of T2DM-
related comorbidities cannot be overlooked due to its
multiple incurred expenditures, either due to a higher
prevalence of hospitalization and visits to the general
practitioner, or due to an increase in the number of drugs
used (American Diabetes Association, 2018). Given that
disproportion, other studies have identified high-cost (HC)
patients in different diseases, such as T2DM or acute coronary
syndrome (Rais et al., 2013; Wodchis et al., 2016).
Characterizing the effects of different comorbidities in HC
patients may represent an opportunity to implement
interventions addressing patient-centered care models to care
better for T2DM patients with complex disease.
Scholars have examined the economic impact of coexisting
chronic disease in T2DM patients based on counting the
number of diseases, but less is known about which specific
types of comorbidities contribute primarily to higher costs
(Kerr et al., 2007). Moreover, several scholars have
investigated the entire T2DM population rather than
focusing on the older T2DM population, which usually
presents a higher percentage of patients with complex
diseases (Illario et al., 2015; Illario et al., 2016). Hence, we
aimed to evaluate: 1) the prevalence, type and cost of
comorbid chronic diseases occurring in T2DM patients
older than 65 years compared with those of a non-T2DM
population older than 65 years; 2) which factors are associated
at a higher cost in T2DM patients.
MATERIALS AND METHODS
Study Design
A retrospective cohort study was carried out using information
collected routinely in a healthcare database in the Campania
Region of Southern Italy. The Campania Region Database
(CaReDB) includes patient-level demographic information,
electronic records of outpatient pharmacy dispensing, and
hospital discharge for ∼6 million residents of a well-defined
region in Italy (∼10% of the Italian population). Data are
tracked longitudinally via de-identified and unique patient
numbers. For the purpose of this analysis, data from 1 January
2017 through 31 December 2018 were used. CaReDB is complete
and includes validated data used in previous drug utilization
studies (Iolascon et al., 2013; Casula et al., 2014; Orlando et al.,
2016; Guerriero et al., 2017; Russo et al., 2018; Orlando et al.,
2020). The characteristics of CaReDB are described in
Supplementary Table S1.
Study Population
The study population consisted of people aged ≥65 years who had
received medication dispensation according to CaReDB between
1 January and 31 December 2017 (enrollment period).
Individuals with T2DM were identified by selecting those who
had received ≥2 prescriptions for antidiabetic drugs alone or in
combination with any type of insulin, as a proxy for disease
diagnosis (Moreno et al., 2019). Individuals who did not receive
any antidiabetic agent during the study period were used as the
comparator group for the analysis and are referred to as “non-
T2DM” cohort.
Patient Characteristics
Comorbidity in T2DM group and non-T2DM group was assessed
using a modified version of the RxRiskV Index, a validated
pharmaceutical-based comorbidity index derived from
dispensation data using Anatomical Therapeutic Chemical
classification codes (O’Shea et al., 2013; Pratt et al., 2018). The
RxRiskV Index was adapted for our study by including updated
Anatomical Therapeutic Chemical codes for medications licensed
in Italy currently (Supplementary Table S2). Individuals were
classified as having one of the conditions listed in the RxRiskV
Index if they received at ≥2 consecutive dispensations of a drug
for treatment of a specific class of disease. Comorbidities were
classified as concordant or discordant on expert opinions’
consensus taking as reference the definition of chronic
comorbidities of T2DM by Piette and colleagues (Piette and
Kerr, 2006). T2DM was excluded from the list because it was
the disease of interest in the present study. Individuals were
categorized by sex and stratified into three age groups; 65–69,
70–74, and ≥75 years. The number of medications dispensed, and
all-cause hospital admissions were estimated in T2DM group and
non-T2DM group.
Outcome
The total cost, related to all comorbidities, was calculated as the
sum of medical costs and dispensed drugs costs for both T2DM
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and non-T2DM group in 2018 (follow-up period). The total
healthcare cost included drug expenses to treat the comorbidities
selected in the RxRisk Index, excluding those attributed directly
to T2DM. The hospitalization cost included the cost of all-cause
hospitalization incurred in each group. In accordance with recent
studies (Meyers et al., 2014; Wammes et al., 2018; Nelson et al.,
2019), primary care visits were proxied using prescriptions.
Therefore, each prescription is counted as a visit. T2DM
patients were classified according to the distribution of the
total cost as HC or “non-high cost” (NHC) individuals. We
created two sub-cohorts of HC T2DM individuals: patients
whose costs were above the 90th percentile of the total cost;
patients whose costs were above the 80th percentile of the total
cost. We also created two sub-cohorts of NHCT2DM individuals,
with costs below the 90th and 80th percentile of the total
healthcare cost. Costs were expressed in euros at time of analyses.
Statistical Analysis
The median level of comorbidity, interquartile range, and
prevalence of the most common comorbid conditions defined
by the RxRiskV Index were assessed in those with T2DM and
those not suffering from T2DM. Descriptive analyses of patient
characteristics were calculated as frequencies and proportions,
and the use of healthcare services as the mean number and
median number of prescriptions, primary care visits, and
hospitalizations. Differences between people suffering from
and not suffering from T2DM were compared using chi-
square test for categorical variables, and the
Wilcoxon–Mann–Whitney test or Student’s t-test for
numerical variables. The annual average cost of drugs and
hospitalizations by sex, age, type, and number of comorbidities
was estimated in the T2DM group and non-T2DM group.
Age- and sex-adjusted logistic regression models were
employed to examine the association between the comorbidity
prevalence rates and T2DM status (T2DM vs non-T2DM group).
A regression model for each comorbidity with a prevalence ≥5%
in T2DM group was created. The adjusted odds ratios (ORs) were
calculated and displayed with their respective 95% confidence
intervals (95% CI).
Among T2DM patients, the sub-cohorts formed by HC
patients and NHC patients were characterized in terms of
demographic variables (sex and age), comorbidity score
(categorized as greater or less than five comorbidities), type of
comorbidity (concordant, discordant, or both), prevalence of
each comorbidity, as well as the use and cost of healthcare
services. To assess predictors of being a HC patient with
T2DM, two logistic regression models, for the >90th and
>80th percentile of the total cost, were performed, respectively.
The demographic variables included as independent variables
were sex (reference: female) and age (reference: 65–69 years). The
clinical variables included were comorbidity score (reference
<5 comorbidities), presence of concordant/discordant
comorbidities, and receipt of insulin (reference: use of insulin).
Data management was carried out with a Microsoft SQL server
v2018 (Penton Media, Loveland, CO, United States). Analyses
were undertaken with SPSS v17.1 (IBM, Armonk, NY, United
States) and p < 0.05 was considered significant.
RESULTS
A total of 1,011,671 people aged >65 years were included in our
study. Among them, 197,992 (19.6%) received ≥2 prescriptions
for antidiabetic drugs and were identified as the T2DM cohort.
The age (mean ± standard deviation, SD) was 74.8 ± 6.7 years
for the T2DM cohort and 74.7 ± 7.5 years for the non-T2DM
cohort. Most individuals (88.5%) had at least one of the
comorbidities of interest, increasing up to 97.6% in the T2DM
group. The median number of comorbid conditions was 5
(Interquartile range, IQR: 3–7) among T2DM patients and 3
(IQR: 1–6) among non-T2DM individuals. Significant differences
between T2DM and non-T2DM cohorts were recorded in the
mean number of prescriptions (38.2 vs. 24.8), primary care visits
(16.5 ± 9.8 vs. 11.2 ± 9.2), percentage of patients who had more
than one hospitalization (20.4% vs. 13.8%) and percentage of
patients with >3 days of stay in hospital as an inpatient (12.3% vs.
8.0%). Characteristics of T2DM and non-T2DM cohorts are
shown in Table 1.
Table 2 shows prevalence of comorbidities and ORs adjusted
by sex and age in T2DM and non-T2DM groups. The vast
majority of comorbidities occurred significantly more
frequently among T2DM patients. Individuals in T2DM
cohort were significantly more likely to have hyperlipidemia as
a comorbid condition than people in the non-T2DM cohort (OR
3.42, 95% CI, 3.38–3.45), followed by hyperuricemia/gout (2.49,
2.45–2.53), cerebrovascular disease (2.82, 2.80–2.85) and
ischemic heart disease/angina (2.17, 2.11–2.22). Among
discordant comorbidities, gastro-oesophageal reflux disease
(GORD) and peptic ulcer was the most prevalent comorbidity
in T2DM group and was more prevalent than that in the non-
T2DM group (OR 2.22, 95% CI, 2.20–2.24). Mental health
conditions were most frequently detected in T2DM cohort:
epilepsy (OR 1.92, 1.88–1.96); depression (OR 1.24, 1.22–1.26).
However, two conditions recorded a significantly lower
prevalence in the T2DM cohort when compared with non-
T2DM cohort: osteoporosis (3.8% and 5.0%, respectively) and
corticosteroid-responsive diseases (6.2% and 9.2%, respectively),
defined as inflammatory conditions generally treated with
mineralocorticoids and glucocorticoids.
The total mean annual cost per patient in the T2DM cohort
due to comorbidities was €7,627 (95% CI: 7,512–7,741) and
€4,401 (4,359–4,443) in the non-T2DM cohort (Table 3A),
and the difference in cost (“cost ratio”) was 1.73. The
hospitalization cost contributed to ∼90% of total cost in both
groups, with a significant difference between the T2DM group
and non-T2DM group (cost ratio: 1.77). The greatest difference
between the two groups was for the hospitalization cost related to
micro/macrovascular complications (cost ratio: 2.38); this
represented ∼40% of the total hospitalization cost in the
T2DM group.
The total mean cost attributable to comorbidities between
T2DM and non-T2DM people, stratified by sex and age, showed
differences that decreased with age (Table 3B). Concordant and
discordant comorbidities showed a higher total cost in T2DM
group, with a cost ratio of 1.89 and 1.25 for concordant and
discordant comorbidities, respectively. Furthermore, as the
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number of comorbidities increased, the average cost per patient
also increased, with around 30% higher costs in the T2DM cohort
(Table 3C).
Among T2DM patients (N  197,992), 19,319 were identified
as being above the 90th percentile of cost distribution (more than
€19,577), and 38,639 as being above the 80th percentile (more
than €2,563) (Table 4). The annual total cost of the T2DM
population included in this study amounted to approximately
€1.47 billion. The HC patients (above the 90th percentile) accrued
costs of more than €1.20 billion, which represented ∼80% of the















Mean age (SD) 74.8 (6.7) 74.7 (7.5) <0.001
65–69 years (%) 26.8 31.5 <0.001
70–74 years (%) 26.2 24.0 <0.001
≥75 years (%) 47.0 44.5 <0.001
Comorbid conditions, median number (IQR) 5 (3–7) 3 (1–6) <0.001
Number of prescriptions — — —
Mean (SD) 38.2 (22.8) 24.8 (20.3) <0.001
Median (IQR) 36 (21–52) 21 (9–37) —
Primary care visits — — —
Mean (SD) 16.5 (9.8) 11.2 (9.2) <0.001
Median (IQR) 15 (10–22) 10 (4–16) —
Hospital admission — — —
Had ≥1 hospitalization (%) 20.4 13.8 <0.001
Mean (SD)a 1.6 (1.1) 1.4 (0.9) <0.001
Median (IQR)a 1 (1–2) 1 (1–2) —
Inpatient days (total) — — —
>3 days, % 12.3 8.0 <0.001
Median (IQR)a 9 (5–17) 8 (5–15) —
T2DM, Type 2 diabetes mellitus; SD, Standard deviation; IQR, Interquartile range.
aAmong patients with ≥1 hospitalization.
TABLE 2 | Chronic comorbidities with ≥5% prevalence in the study population with and without type-2 diabetes mellitus (T2DM).
T2DM cohort (%) NON-T2DM cohort (%) Or (95% CI)a
Concordant conditions — — —
Ischaemic heart disease/Angina 5.0 2.3 2.166 (2.112–2.221)
Cerebrovascular disease 50.1 26.1 2.824 (2.796–2.853)
Arrhythmia 7.1 6.0 1.157 (1.135–1.180)
Renal disease 35.6 26.6 1.493 (1.478–1.509)
Heart disease 52.8 35.9 1.991 (1.971–2.011)
Hyperlipidemia 60.4 30.7 3.417 (3.382–3.452)
Hyperuricemia/Gout 12.9 5.5 2.491 (2.450–2.532)
Hypertension 42.7 31.5 1.625 (1.609–1.642)
Discordant conditions — — —
Coagulation disorders 11.7 8.6 1.382 (1.360–1.404)
Benign prostatic hypertrophy 15.4 12.7 1.141 (1.124–1.159)
Chronic airways disease 16.3 13.6 1.205 (1.189–1.221)
GORD and peptic ulcer 67.9 48.7 2.220 (2.197–2.243)
Glaucoma 8.4 4.9 1.776 (1.742–1.809)
Hypothyroidism 7.2 5.5 1.431 (1.403–1.459)
Osteoporosis 3.8 5.0 0.804 (0.783–0.824)
Inflammatory/Pain 25.9 21.1 1.340 (1.325–1.355)
Pain (treated with opiates) 5.3 3.4 1.605 (1.568–1.642)
Corticosteroid-responsive diseasesb 6.2 9.2 0.657 (0.644–0.670)
Depression 10.4 8.7 1.238 (1.217–1.258)
Epilepsy 7.6 4.1 1.917 (1.879–1.956)
GORD, Gastro-oesophageal reflux disease; OR, Odds ratio; CI, Confidence interval.
aAdjusted by sex and age.
bDefined as inflammatory conditions generally treated with mineralocorticoids and glucocorticoids.
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total cost. HC patients (above the 80th percentile) accrued costs
of more than €1,39 billion, which represented ∼90% of the total
cost related to this population. Differences were found between
HC patients and NHC individuals in terms of age and sex
distribution (Table 4). The cost increased with the
comorbidity score. More than 85% of HC patients above the
90th percentile and >75% of HC patients above the 80th
percentile had ≥5 chronic comorbidities. Higher use of insulin
was recorded for HC patients (39.3 and 35.1%, respectively, for
people above the 90th percentile and above the 80th percentile of
costs), than for NHC individuals (24.4 and 23.6%, respectively for
subjects above the 90th percentile and below the 80th percentile
of costs). The most common conditions in individuals above the
90th and 80th percentile of the total cost were: GORD and peptic
ulcer (86.5 and 79.9%, respectively), hyperlipidemia (70.3 and
65.1%, respectively) and heart disease (70.0 and 61.5%,
respectively) (Figure 1). With regard to variables in use of
healthcare services, HC patients had a significantly higher
number (mean ± SD) of annual visits in primary care than
that for NHC individuals (22.3 ± 10.4 vs. 16.4 ± 9.3 in people
above and below the 90th percentile; 20.4 ± 10.5 vs. 16.1 ± 9.2 in
individuals above and below the 80th percentile) and higher
number (mean ± SD) of prescriptions (54.8 ± 23.8 vs. 37.2 ± 21.6
in people above or below the 90th percentile; 49.4 ± 24.6 vs. 36.4 ±
21.1 in individuals above or below the 80th percentile). More than
half of people above the 90th percentile was hospitalized at least
twice per year (this figure was almost 100% if we measured those
who were hospitalized at least once). Only 1.7% of people below
the 90th percentile recorded a number of hospitalizations per year
>2, and ∼12% were hospitalized at least once a year. Looking at






Total 7,627.0 (7,512.3–7,741.5) 4,401.4 (4,359.5–4,443.3) 1.73
Drug costa 615.9 (611.8–620.0) 438.8 (437.1–440.5) 1.40
Micro/Macro vascular hospitalization cost 2,849.1 (2,775.7–2,922.4) 1,197.2 (1,173.1–1,221.3) 2.38
Other causes hospitalization cost 4,161.9 (4,083.5–4,240.3) 2,765.3 (2,733.8–2,797.0) 1.51
Total hospitalization costb 7,011.0 (6,897.0–7,125.0) 3,962.6 (3,920.9–4,004.2) 1.77
CI, Confidence Interval.
aIncludes all drugs for the treatment of comorbidities.
bIncludes all hospitalizations due to both complications and comorbidities.






Sex — — —
Female 6,716.4 (6,573.6–6,859.2) 3,903.1 (3,852.2–3,954.0) 1.72
Male 8,669.4 (8,485.9–8,852.8) 5,091.8 (5,021.0–5,162.5) 1.70
Age group — — —
65–69 years 6,651.9 (6,438.9–6,864.8) 3,226.4 (3,161.0–3,291.8) 2.06
70–74 years 7,873.7 (7,638.9–8,108.5) 4,387.9 (4,300.3–4,475.5) 1.79
≥75 years 8,033.8 (7,867.8–8,199.7) 5,174.8 (5,108.8–5,240.9) 1.55
CI, Confidence Interval.






Concordant comorbidities 1,965.4 (1,853.1–2,077.6) 1,041.5 (1,009.3–1,073.7) 1.89
Discordant comorbidities 1,466.4 (1,338.7–1,594.1) 1,177.6 (1,140.0–1,215.2) 1.25
Number of comorbiditiesa — — —
1 618.1 (563.1–673.0) 452.8 (439.3–466.2) 1.37
2 1,524.8 (1,439.2–1,610.5) 1,132.8 (1,104.8–1,160.8) 1.35
3 2,564.4 (2,445.7–2,683.1) 1,979.4 (1,934.5–2,024.4) 1.30
4 3,841.8 (3,690.7–3,993.0) 3,086.7 (3,018.6–3,154.7) 1.24
≥5 10,867.6 (10,687.8–11,047.3) 8,124.4 (8,031.7–8,217.2) 1.34
CI, Confidence Interval.
aIncremental cost for each comorbidity in addition to T2D.
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number of inpatient days subjects above the 90th percentile of
costs recorded 18.4 [19.9] mean number [SD] vs 8.4 [7.1] in
patients below the 90th percentile. The largest difference between
T2DM patients above the 90th percentile and 80th percentile of
the total-cost distribution and T2DM patients below the 90th
percentile and 80th percentile of total-cost distribution was the
hospitalization cost, which was markedly higher among HC
patients than NHC patients in both groups (Table 4).
Logistic regression (Figures 2A) showed that a person in the
oldest age group (≥75 years) was more likely to be a HC T2DM
patient (in the top-10 or top-20 decile of the cost distribution)
than a person in the younger age group. Men were ∼43% more
likely to be HC patients (in both groups) compared with women.
The strongest predictor of being a HC T2DM patient (in the top-
10 decile or top-20 decile of the cost distribution) was having ≥5
comorbidities (top-10: OR 3.65, 95% CI, 3.49–3.82; top-20: 1.94,
1.88–1.99).
In addition, insulin use was associated with becoming a HC
patient (top-10: OR 1.74, 95% CI, 1.68–1.79; top-20: 1.61,
1.57–1.65) and having discordant and concordant
comorbidities was a strong predictor of being a HC patient in
the top-10 decile (2.76, 2.42–3.15) or in top-20 decile of the cost
distribution (1.76, 1.66–1.88) (Figures 2A). Furthermore, among
concordant comorbidities, renal impairment was the strongest
predictor of being a HC patient (top-10: 2.03, 1.96–2.09; top-20:
2.15, 2.10–2.20) followed by hyperuricemia/gout (90th: 1.41,
1.36–1.47; 80th: 1.30, 1.26–1.35). Among discordant
comorbidities, GORD and peptic ulcer (90th: 1.49, 1.42–1.56;
80th: 1.31, 1.27–1.35) and corticosteroid-responsive diseases
(90th: 1.51, 1.43–1.59; 80th: 1.38, 1.32–1.44) showed a higher
likelihood of a person becoming a HC patient (Figures 2B).
DISCUSSION
We investigated prevalence and cost of comorbid conditions,
concordant and discordant with T2DM, in a population of
1,011,671 individuals aged >65 years. We also examined and
quantified differences in healthcare costs between HC and
NHC T2DM patients identifying the type and number of
comorbidities in the top-10 and top-20 percentiles of the cost
distribution.
T2DM presented a higher prevalence of comorbidities and
related cost compared with that in non-T2DM population. Our
results are in accordance with data from Ireland and Australia
(Caughey et al., 2010; O’Shea et al., 2013). Overall, cardiovascular
diseases represented a substantial part of concordant
comorbidities in the T2DM group and non-T2DM group, but
the prevalence of ischaemic heart disease/angina was twofold
higher in T2DM group compared with that in non-T2DM group.
The relationship between T2DM and cardiovascular diseases
reflects the impairments induced by T2DM on the
cardiovascular system (Huang et al., 2017; Haas and
McDonnell, 2018). The most prevalent concordant conditions
among T2DM patients were hyperlipidemia, heart disease and
atherosclerosis, with a greater prevalence in T2DM patients
compared with that in non-T2DM individuals (Reunanen
et al., 2000; Caughey et al., 2010; Huber et al., 2014; Chima
et al., 2017). Another concordant comorbidity more likely to be
recorded in T2DM patients was hyperuricemia/gout (OR 2.49,
95% CI, 2.45–2.53). As reported recently, there appears to be a
three-way association between hyperuricemia, T2DM, and
hypertension (Mortada, 2017). Moreover, hyperuricemia has
emerged as an independent risk factor in T2DM development
and hypertension through several postulated mechanisms
(Kuwabara et al., 2017). The most prevalent discordant
comorbidity in T2DM patients was GORD and peptic ulcer
(67.9%), which was more than twice as likely to appear in
T2DM patients than in non-T2DM individuals (OR 2.22, 95%
CI, 2.20–2.24). A recent meta-analysis suggested that patients
with T2DM are at a greater risk of GORD (Sun et al., 2015).
Different hypotheses may be considered to justify this association,
such as the higher prevalence of obesity and autonomic
neuropathy among patients with T2DM (Frøkjær et al., 2007;
De Vries et al., 2008). T2DMduration could also influence GORD
and peptic ulcer symptoms, and could justify the higher
prevalence of prescribed medication for this comorbidity in
our cohort over 65 years of age (Kinekawa et al., 2008).
Conversely, we must take into account that higher frequency
of co-prescribing gastro-protective agents could be due to
concomitant treatment with antiplatelet agents or
anticoagulant medications rather than to the presence of
gastroenteric diseases, as reported in studies carried out in
Ireland and Australia using the RxRiskV Index to evaluate
comorbidities in older T2DM patients (Caughey et al., 2010;
O’Shea et al., 2013). During the study period, T2DM group
showed a higher prevalence of comorbidities (concordant and
discordant) with the exception for osteoporosis and
corticosteroid-responsive disease. These results support the
hypothesis of an Australian study by Caughey et al. (2010),
who argued that these findings may infer an inadequacy in
prescribing anti-osteoporosis medication level to older people
with T2DM. A lower prevalence of corticosteroid-responsive
disease was recorded in T2DM group. This finding could
indicate restricted use of these drugs in T2DM due the
predictable adverse effects of glucocorticoid therapy on blood
glucose levels (Wallace and Metzger, 2018; Ceccarelli et al., 2019).
An increase in complexity in terms of comorbidity leads to
increased costs. We showed that the average total annual cost due
to concordant and discordant comorbidities was ∼70% higher in
patients with T2DM than in people not suffering from T2DM.
The worldwide economic impact of T2DM is well known (Giorda
et al., 2011) because treatment of the complications associated
with this disease is responsible for most of the management cost.
Nevertheless, we highlighted that incremental cost for each
comorbidity in addition to T2DM was related to concordant
and discordant comorbidities. Therefore, one should not neglect
discordant comorbidities in assessment of the cost associated
with T2DM in future economic evaluations.
The comparison of cost among different countries is complex
due to differences between healthcare systems. However, in
agreement with several studies (Simpson et al., 2003; Bruno
et al., 2012; Pagano et al., 2016), the greatest difference in cost
of care between T2DM and non-T2DM groups was due to
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hospitalization. The influence of comorbidities on inpatient-care
cost tended to be greater among patients with T2DM. This
finding may also be because the duration of inpatient stay
may increase with an increasing number of complications in
T2DM patients (Jacobs et al., 1991). A higher percentage of
patients who spent >3 days as hospital inpatients in the T2DM
group than in the non-T2DM group was noted (12.3 vs. 8.0,
respectively).
We also evaluated T2DM patients by categorizing them
according to the cost distribution. We identified patients who
were HC (i.e., above the 80th and above the 90th percentile).
These patients were responsible for ∼80% of the use of healthcare
services (primary care visits and/or hospital admissions and drug
costs). These results are consistent with estimates reported by
Zhang et al. (2017), who also suggested a significant skew in costs
for T2DM patients. The high comorbidity-cost concentration
indicated that it might be worthwhile to analyze patients
requiring more expensive care by identifying, as Meyers et al.,
two subgroups of diabetic patients: those accruing for top 10th
and those accruing for top 20th percentile of cost distribution
(Meyers et al., 2014). These groups include all patients with
significant economic and clinical burdens. Consistent with our
analyses, other scholars have found that hospitalization
accounted for almost all total spending among HC patients
(Meyers et al., 2014; Rice et al., 2017; Nelson et al., 2019).
Almost all of our HC patients were hospitalized at least once
during 12-month follow-up, whereas Meyers and colleagues
showed a lower (but explainable) figure because our study
population was aged >65 years.
Our findings highlight the comorbidity score to be the
strongest predictor of becoming an HC healthcare user: the
higher is the number of comorbid conditions, the more costly
and resource-consuming are patients. T2DM patients were
significantly more likely to be in the top-10 percentile or the
top-20 percentile of the total cost distribution if they had ≥5
comorbidities. This finding has enormous relevance considering
TABLE 4 | Characteristics of high-cost and low–cost T2DM patients.
T2DM cohort
High–cost Non-high–cost High–cost Non-high–cost
Patients Patients Patients Patients
Above 90th percentile Below 90th percentile Above 80th percentile Below 80th percentile
N = 19,319 N = 173,870 N = 38,639 N = 154,550
Sex, N (%) — — — —
Female 9,244 (47.8) 93,879 (54.0) 18,473 (47.8) 84,650 (54.8)
Male 10,075 (52.2) 79,991 (46.0) 20,166 (52.2) 69,900 (45.2)
Age, N (%) — — — —
65–69 years 4,271 (22.1) 46,739 (26.9) 9,123 (23.6) 41,887 (27.1)
70–74 years 5,062 (26.2) 45,641 (26.3) 10,109 (26.2) 40,594 (26.3)
≥75 years 9,986 (51.7) 81,490 (46.9) 19,407 (50.2) 72,069 (46.6)
Age mean (SD) 75.3 (6.4) 74.7 (6.8) 75.1 (6.5) 74.8 (6.8)
Comorbidity score — — — —
Mean (SD) 7.3 (2.4) 5.2 (2.5) 6.4 (2.6) 5.1 (2.5)
Median (IQR) 7 (6–9) 5 (3–7) 6 (5–8) 5 (3–7)
Comorbidity score, N (%) — — — —
<5 comorbidities 2,447 (12.7) 72,237 (41.5) 9,285 (24.0) 65,399 (42.3)
≥5 comorbidities 16,872 (87.3) 101,633 (58.5) 29,354 (76.0) 89,151 (57.7)
Insulin use (%) 7,600 (39.3) 42,496 (24.4) 13,569 (35.1) 36,527 (23.6)
Primary-care visits — — — —
Mean (SD) 22.3 (10.4) 16.4 (9.3) 20.4 (10.5) 16.1 (9.2)
Median (IQR) 21.0 (15–28) 15 (10–21) 19 (13–26) 15 (10–21)
Number of prescriptions — — — —
Mean (SD) 54.8 (23.8) 37.2 (21.6) 49.4 (24.6) 36.4 (21.1)
Median (IQR) 53 (39–68) 35 (21–50) 47 (32–63) 34 (20–49)
Hospital admission, N (%) — — — —
≥1 19,299 (99.9) 21,090 (12.1) 37,139 (96.1) 3,250 (2.1)
≥2 10,195 (52.8) 2,898 (1.7) 12,966 (33.6) 127 (0.1)
Inpatient days — — — —
>3 days, N (%) 15,748 (81.5) 8,312 (4.8) 23,646 (61.2) 414 (0.3)
Mean (SD) 18.4 (19.9) 8.4 (7.1) 14.9 (17.2) 8.5 (11.2)
Median (IQR) 11 (6–23) 7 (4–10) 9 (5–17) 6 (4–9)
Drug cost (€) — — — —
Mean (95% CI) 1,119.0 (1,091.8–1,146.1) 560.0 (556.7–563.3) 1,036.6 (1,019.0–1,054.2) 510.7 (508.3–513.1)
Hospitalization cost (€) — — — —
Mean (95% CI) 60,843.3 (6,0044.4–61,642.3) 1,029.6 (1,013.8–1,045.4) 34,938.9 (34,461.7–35,416.1) 28.7 (27.6–29.8)
Total cost (€) — — — —
Mean (CI) 61,962.3 (61,161.9–62,762.7) 1,589.6 (1,573.4–1,605.8) 35,975.6 (35,497.5–36,453.6) 539.5 (536.9–542.0)
CI, Confidence interval; SD, standard deviation; IQR, interquartile rang.
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that 50% of our T2DMpatients had ≥5 comorbidities. A systematic
review of the literature revealed that clinicians face a diverse range
of challenges when dealing with multimorbid patients such as
T2DM patients: fragmented healthcare services/systems; following
multiple guidelines focusing on the management of a single
condition; delivering patient-centered care; barriers to shared
decision-making (Sinnott et al., 2013). Together with the
comorbidity score, age, male sex and insulin treatment were the
other markers of the cost of HC patients.
Our results emphasize the need for primary prevention through
healthcare promotion and education. Moreover, the healthcare
system should take into consideration the special needs of T2DM
patients with comorbidities, and implement a multidisciplinary
organization of care that can develop appropriate diagnostic and
therapeutic strategies “tailored” to the specific needs of this group
of patients. The heterogeneity of multimorbidity often necessitates
a holistic and integrated approach to ensure that optimal care is
provided for all co-existing conditions (The Academy of Medical
Sciences, 2018). In fact, managing individual conditions separately
may be ineffective and inefficient. Conversely, coordinated services
can contribute to maximize healthcare efficiency and focus on the
specific healthcare needs of each patient. When we analyzed the
importance of each comorbidity in relation to a high cost, almost
all of them contributed to the top decile of cost. Specifically, GORD
and peptic ulcer, hyperlipidemia, cerebrovascular disease, and renal
impairment were the more important conditions associated with a
high cost; among them, the one with the greatest economic impact
was renal impairment.
In agreement with the work of other scholars (An and Le, 2016;
Lin et al., 2018), concordant and discordant conditions were more
prevalent in T2DM patients and were associated with a higher cost
of care. It is well known that disease-specific comorbidities
represent an important economic burden in patients with
T2DM. However, less attention has been paid to other types of
comorbidities (Boyd et al., 2005). This factor must be considered
particularly if T2DM patients are hospitalized for any of these
conditions because the hospitalization cost represents the major
determinant of the high cost, and is proportional to the duration of
hospital stay. This, in turn, may be reduced by optimizing initiation
of blood-glucose control, if possible, before hospital admission.
FIGURE 1 | (A) Characteristics of high-cost and non-high-cost T2DM patients. (B) Proportions of comorbidities in high-cost and non-high-cost T2DM patients.
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Our study had twomain strengths. First, it had a population-based
design within the Italian public-health system among T2DM patients
over 65 years of age. Consequently, our data reflect a picture of
comorbidities in T2DM and non-T2DM patients by identifying
specific predictors of use of healthcare resources. Second, our study
contributes to understanding of the determinants of an imbalanced
distribution of comorbidity costs among T2DM patients. It also
underlies the need to consider holistic medical care to better
manage complex disease which determines high healthcare costs.
In order to prevent negative consequences of T2DM in older patients,
it would be necessary to provide some recommendations on lifestyle
for patients who are below 65 years of age or who are suspected to
become diabetics due to family history. The early identification of the
suspected comorbidities can provide a framework for modifying the
lifestyle in order to reduce the ultimately cost of therapy as well as to
improve the quality of life despite of T2DM disease.
Our study had three main limitations. The first was the nature of
the Italian administrative database used to obtain data. Although
powerful tools, pharmaceutical records do not provide information
about private-practice prescriptions and out-of-pocket expenditure.
Thus, the prevalence of some diseases reported in our analysis may
have been underestimated. However, patients who take drugs long-
term are unlikely to buy them over-the-counter. The second
limitation was the lack of information relating to the causal
relationship between patient characteristics and healthcare costs
among T2DM patients. Third, we limited our cohorts to patients
over 65 years of age, so the results apply strictly to this age group.
CONCLUSION
We demonstrated a greater prevalence of most concordant and
discordant T2DM-related comorbidities and the associated cost
in older patients compared with those not suffering from T2DM.
HC T2DM patients accrued >80% of the total cost for
comorbidities, and this cost increased in parallel with an
increasing number of comorbidities. Our study strengthens the
importance of implementing integrated care models, which
include a holistic and patient-tailored focus, to achieve more
efficacious T2DM care in the context of the growing proportion
FIGURE 2 | (A) Predictors of being a high-cost T2DM patient. (B) Predictive comorbidities of being a high-cost T2DM patient. Notes: Both multivariate regression
models are adjusted for sex and age.
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of multimorbidity in the older population. Moreover, it
underlines the need to reduce the number of hospitalizations
and duration of hospital stay due to T2DM. Among other factors,
this can be achieved by intensifying control of blood glucose
before hospital admission for elective procedures. Finally, this
study can be a useful tool for healthcare stakeholders when
planning future interventions to track and reduce the cost of
T2DM-related disease.
Contribution to the Field
T2DM prevalence has increased dramatically worldwide to become
an important healthcare concern, occurring particularly in those
aged ≥65 years. Furthermore, the resulting health and economic
T2DM impacts go beyond the condition itself because diabetic
patients are subject to disabling complications and incur very
high costs to the Italian National Health Service. To date, little is
known about the specific comorbidities contributing to higher costs
in patients with T2DM, particularly in older patients. The
retrospective cohort study proposed here describes the prevalence,
type, and cost of comorbidities occurring in older patients with
T2DMand correlationwith high cost patients. It therefore seems that
there is a greater prevalence of most T2DM-related comorbidities
and the associated cost in older patients compared with those not
suffering from T2DM. Hence, it appears that HC T2DM patients
accrued >80% of the total cost for comorbidities, and this cost
increased in parallel with an increasing number of comorbidities.
These findings reflect the importance of implementing integrated
care models, which include a holistic and patient-tailored focus, to
achieve more efficacious T2DM care in the context of the growing
proportion of multimorbidity in the older population.
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